Rostislav Christov Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRXGet Free Report) Director Rostislav Christov Raykov sold 2,431 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of C$6.67, for a total transaction of C$16,212.34.

Rostislav Christov Raykov also recently made the following trade(s):

  • On Wednesday, September 4th, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$7.45, for a total transaction of C$18,115.81.

Fennec Pharmaceuticals Trading Up 1.8 %

TSE FRX opened at C$6.26 on Friday. Fennec Pharmaceuticals Inc. has a 12-month low of C$6.14 and a 12-month high of C$15.43. The company has a fifty day simple moving average of C$7.46 and a two-hundred day simple moving average of C$9.77. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68. The stock has a market cap of C$171.27 million, a P/E ratio of 69.56 and a beta of 0.26.

Fennec Pharmaceuticals (TSE:FRXGet Free Report) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.08 by C($0.35). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. The firm had revenue of C$9.94 million during the quarter, compared to analyst estimates of C$18.67 million. On average, analysts forecast that Fennec Pharmaceuticals Inc. will post 0.6025751 earnings per share for the current year.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Featured Articles

Insider Buying and Selling by Quarter for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.